Paxil CR In Recovery, But Still Hobbling GSK’s U.S. Rx Sales Growth

Controlled-release paroxetine recaptures 41% of pre-seizure new prescription share, but the sales interruption still slows growth of GSK’s U.S. pharma business during the second quarter.